The ongoing opioid crisis in the U.S. is harrowing – 91 Americans die every day from an opioid overdose, according to the Centers for Disease Control & Prevention. Companies are searching for innovative ways to deliver opioid maintenance treatment to patients that are hoping to get clean.
Buprenorphine is a compound used for medication-assisted treatment, traditionally administered as a tablet or a patch. When Titan Pharmaceuticals (NSDQ:TTNP) began early testing of its buprenorphine implant, patients were eager to get their hands on the product.
“More than 80% of the patients who completed the first 6 months wanted to enroll in the second 6 months,” CEO Sunil Bhonsle told Drug Delivery Business News.
Get the full story at our sister site, Drug Delivery Business News.